KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Prevention of oral mucositis in patients undergoing cancer chemotherapy using betamethasone mouthwash: A multicenter randomized controlled trial protocol. PMID 41950207 · PLoS One · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and Clinical Relevance of Adjunctive Cariprazine Treatment in Patients with Major Depressive Disorder: Post Hoc Analyses from a Phase III Study. PMID 41948533 · Neuropsychiatr Dis Treat · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Hypomagnesemia Associated with Omeprazole Use in Patients Treated with Platinum Derivatives: An Exploratory Randomized Placebo-Controlled Clinical Trial. PMID 41938717 · Can J Hosp Pharm · 2026 The record describes a randomized trial with a drug intervention and mentions Kaplan-Meier analysis. However, the primary endpoint is the rate of magnesium depletion (a safety/biomarker outcome), not a key oncologic time-to-event efficacy endpoint. Furthermore, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III, and the study is exploratory in nature, focusing on safety rather than treatment efficacy.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of perioperative immune checkpoint inhibitors combined with chemotherapy versus chemotherapy alone for locally advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized phase III trials. PMID 41924604 · Front Oncol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Rezivertinib in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR Study. PMID 41924561 · Cancer Commun (Lond) · 2026 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 2 Figure · 3 Panel · risk visible
Efficacy and safety of efgartigimod in the treatment of impending myasthenic crisis. PMID 41909657 · Front Immunol · 2026 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Constrained Hierarchical Bayesian Model Considering Latent Biomarker Subgroups for Time-To-Event Endpoints in Randomized Phase II Trials. PMID 41905407 · Pharm Stat · 2026 The record is a statistical methodology paper proposing a model for future trials, not an original report of a completed trial's results. It does not contain a drug intervention or present trial efficacy data.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ruxolitinib treatment in patients with polycythemia vera reduces JAK2 variant allele frequency and improves symptom burden and hematocrit control. PMID 41890273 · Ther Adv Hematol · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety and feasibility of a layered embolization strategy with drug-eluting and uniform-caliber microspheres for advanced hepatocellular carcinoma and unresectable liver metastases: a prospective single-arm clinical trial. PMID 41889406 · Front Oncol · 2026 The study is a prospective single-arm trial, not randomized. It does not report a Phase III or Phase II/III designation. Most importantly, it lacks any primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The efficacy endpoints are limited to short-term imaging response (disease control rate) and biomarker dynamics, which are not time-to-event outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Study protocol: A randomized controlled trial of chemoradiotherapy versus chemotherapy as neoadjuvant therapy for resectable pancreatic cancer (CSGO-HBP-027). PMID 41886441 · PLoS One · 2026 方案论文未报告临床试验结果。
S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
The Effect of Breast Cancer and Breast Self-Examination Health Education on Awareness, Beliefs, and Practices of Female Students at the Faculty of Health Sciences of a University in Somalia. PMID 41885785 · Breast J · 2026 Eligible for oncology, human, randomized, and original results, but excluded due to lack of drug intervention and time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Symptom relief and cytokine modulation by clarithromycin in mild COVID-19 pneumonia: an exploratory, multicenter, randomized-controlled open-label trial (CAME-COVID study). PMID 41884792 · Ther Adv Infect Dis · 2026 The study is a randomized controlled trial of clarithromycin for COVID-19 pneumonia, not an oncology (human malignant neoplasm) study. It lacks a Phase III designation and does not report a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and health-related quality of life associated with second-line vedolizumab after first-line treatment with one anti-TNF in patients with ulcerative colitis: a meta-analysis of the GEMINI-1 and VISIBLE-1 trials. PMID 41883697 · Ther Adv Gastroenterol · 2026 The record is a meta-analysis of ulcerative colitis trials, which is non-oncology, and focuses on clinical remission as the primary endpoint, not a time-to-event outcome like OS or PFS.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Assessment of flonoltinib maleate versus ruxolitinib phosphate in intermediate- to high-risk myelofibrosis (FMF-02): study protocol for a multicenter, randomized, open-label phase IIB trial. PMID 41883618 · Ther Adv Hematol · 2026 This is a protocol for an ongoing randomized, phase IIb trial. While it meets criteria for oncology, human, randomized, and drug intervention, it does not report any results. Furthermore, the primary endpoint (proportion with >=35% spleen volume reduction at week 24) is a categorical response, not a time-to-event endpoint. No time-to-event data or analysis (e.g., OS, PFS, DFS, Kaplan-Meier, HR) is presented.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of Ropivacaine-Based Thoracic Paravertebral Block versus Erector Spinae Plane Block on Quality of Recovery in Laparoscopic Colorectal Cancer Surgery: A Randomized Controlled Trial. PMID 41873336 · Drug Des Devel Ther · 2026 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Depemokimab demonstrates efficacy in patients with type 2 asthma with comorbid CRSwNP: Phase III SWIFT-1/-2 analysis. PMID 41868651 · Front Allergy · 2026 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Nasopharyngeal Carcinoma in Non-Endemic Regions: A Single-Arm Phase 2 Clinical Trial. PMID 41859748 · Cancer Manag Res · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Neoadjuvant chemoradiotherapy with or without PD-1 inhibitors in MMR-proficient non-metastatic rectal cancer: a meta-analysis of randomized controlled trials. PMID 41853263 · Front Immunol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of ilaprazole for stress ulcer - associated upper gastrointestinal bleeding prophylaxis in critically ill patients: a randomized, double-blind, non-inferiority phase 3 trial. PMID 41852672 · Ann Intensive Care · 2026 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Implementing a successful patient navigation program for follow-up colonoscopy: Lessons from the PRECISE study. PMID 41849281 · PLoS One · 2026 The record describes a randomized trial of a patient navigation intervention to improve colonoscopy completion rates after abnormal FIT screening, not a drug trial. It lacks the required drug intervention and time-to-event efficacy endpoint (OS/PFS/DFS/etc., HR, Kaplan-Meier) for inclusion in the oncology KM digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Amino Acid-Based Enteral Nutrition Enhances Postoperative Recovery in Colorectal Cancer Patients: A Randomized Controlled Trial. PMID 41848576 · Nutr Cancer · 2026 The study is a randomized controlled trial in human colorectal cancer patients, but it is excluded because: 1) it evaluates nutritional formulas, not a drug intervention; 2) no Phase III/IIIb or Phase II/III classification is provided (phase unclear); 3) the primary endpoints are nutritional, recovery, and safety metrics, not time-to-event oncology efficacy endpoints (e.g., OS, PFS, DFS). Therefore, it does not meet the criteria for inclusion in the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of nursery phase feeding budgets on growth performance and economics in weanling pigs. PMID 41841043 · Transl Anim Sci · 2026 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Sex-based heterogeneity in response to first-line immunotherapy plus chemotherapy in advanced esophageal squamous-cell carcinoma: a meta-analysis. PMID 41836421 · Front Immunol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Vebreltinib for Previously Treated Astrocytoma, IDH-Mutant, Grade 4, and Glioblastoma, IDH Wild-Type with PTPRZ1-MET Fusion Gene: A Multicenter, Phase III Randomized, Open-Label Trial. PMID 41821581 · Cancer Commun (Lond) · 2026 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 3 Panel · risk unclear
Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study. PMID 41818162 · CA Cancer J Clin · 2026 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type no_km 0 Figure · 0 Panel · risk not_applicable
The effects of abaloparatide on acetabular bone mineral density and proximal femur strength in men with osteoporosis. PMID 41812602 · J Clin Densitom · 2026 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Qu-Shi-Jie-Du Decoction for Prevention of Recurrence and Metastasis in High-Risk Stage II/III Colon Cancer: Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Trial. PMID 41810508 · Integr Cancer Ther · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Advances in Systemic Therapy for Unresectable Hepatocellular Carcinoma: Commentary on The Impact of the STRIDE Regimen in HIMALAYA Trial. PMID 41799527 · Oncol Res · 2026 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Radiotherapy plus immune checkpoint inhibitors versus immune checkpoint inhibitors alone for non-small cell lung cancer with bone metastases: a systematic review and meta-analysis of comparative cohort studies. PMID 41798915 · Front Immunol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Advances in intravenous thrombolysis with tenecteplase in the ultra-time window. PMID 41798825 · Front Neurol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE). PMID 41795905 · Pediatr Dermatol · 2026 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of solriamfetol treatment on sleep quality in Chinese patients with OSA-EDS: results of a randomized controlled trial. PMID 41788715 · Front Med (Lausanne) · 2026 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
First-Line Serplulimab versus Other Anti-PD-1/PD-L1 Antibodies Plus Chemotherapy for Esophageal Squamous Cell Carcinoma: A Systematic Review with Benefit-Risk Assessment via Matching-Adjusted Indirect Comparison. PMID 41788456 · Biologics · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of rimegepant 75 mg orally disintegrating tablet for the acute treatment of chronic rhinosinusitis in adults: Results from a multicenter, randomized, placebo-controlled, phase 2/3 trial. PMID 41779821 · PLoS One · 2026 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Intramuscular Generic Injection (QLG2072) versus Haloperidol in Chinese Patients with Acute Agitation: A Phase 3 Multicenter, Randomized, Double-Blind, Active-Controlled Trial. PMID 41778148 · Drug Des Devel Ther · 2026 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Partially covered or uncovered metal stent efficacy in malignant unresectable distal biliary obstruction (METARSI): Randomized multicenter trial. PMID 41777335 · Endosc Int Open · 2026 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Quality of Recovery After Laparoscopic Ovarian Cystectomy: A Randomized Controlled Trial Comparing Opioid-Free Multimodal Analgesia Versus Opioid-Based Anesthesia. PMID 41773363 · Clin Ter · 2026 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Hybrid Machine Learning Method and Standard Data Analysis Approaches for Predicting Treatment Outcomes of Cardiovascular Diseases: A Randomized Controlled Trial. PMID 41773358 · Clin Ter · 2026 The study is not in oncology and does not involve a drug intervention, which are mandatory criteria for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Intertransverse Process Block versus Erector Spinae Plane Block as Adjuncts to an Interpectoral Block for Breast Cancer Surgery: A Randomized Controlled Trial. PMID 41768106 · J Pain Res · 2026 The trial is a randomized, oncology (breast cancer) study but evaluates anesthetic techniques, not a drug intervention for efficacy. The primary endpoint is morphine consumption (a safety/efficacy measure), not a time-to-event endpoint like OS or PFS. Therefore, it does not meet the core eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The effectiveness of the AI-based RehabLung mobile rehabilitation system on cardiopulmonary function and user satisfaction in lung cancer patients undergoing thoracic surgery: a protocol for a two-arm randomized clinical trial. PMID 41762649 · Ther Adv Respir Dis · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Reversal of Pharmacologic Mydriasis in Pediatric Subjects with Ryzumvi (0.75% Phentolamine Ophthalmic Solution): A Post-Hoc Pooled Analysis from Three Randomized, Placebo-Controlled Phase 3 Trials. PMID 41743463 · Clin Ophthalmol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Impact of soybean meal levels in grow-finisher pig diets for growth and nutrient metabolism. PMID 41743422 · Transl Anim Sci · 2026 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Validation of the Zürich composite measure pain scale (ZCMPS) for abdominal pain assessment in cows. PMID 41740193 · Vet Anaesth Analg · 2026 仅见动物/临床前证据,不是人体临床试验。
H
仅历史库存 excludednon_human pending 0 Figure · 0 Panel · risk -
SAFFRON-301: a randomised phase III study of sitravatinib in combination with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer. PMID 41737914 · BMJ Oncol · 2026 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 1 Figure · 3 Panel · risk visible
Assessment of the Effectiveness, Tolerability, and Safety of the Preservative-Free Fixed Combination of Timolol, Dorzolamide, and Brimonidine Compared to Separate Therapies in Patients with Glaucoma, a Randomized Controlled Trial. PMID 41737851 · Clin Ophthalmol · 2026 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A short-term, exploratory randomized controlled trial on the safety and feasibility of intraoperative raltitrexed peritoneal chemotherapy in laparoscopic radical resection for advanced colorectal cancer. PMID 41737519 · Front Surg · 2026 The study is an exploratory randomized trial in oncology with a drug intervention, but it is not a Phase III or definitive trial, and its primary endpoints are safety/feasibility, not a time-to-event efficacy endpoint required for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cost-effectiveness of ramucirumab plus paclitaxel as maintenance therapy for patients with advanced HER2-negative gastric or gastroesophageal junction cancer. PMID 41737486 · Front Oncol · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass). PMID 41732658 · Ther Adv Med Oncol · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Flavored Vitamin-Mineral Supplementation via Water Improves the Performance of Newly Weaned Piglets. PMID 41721600 · Anim Sci J · 2026 仅见动物/临床前证据,不是人体临床试验。
H
仅历史库存 excludednon_human pending 0 Figure · 0 Panel · risk -
Targeting the neuroimmune axis in prurigo nodularis: a critical appraisal of the nemolizumab trials. PMID 41712432 · Expert Opin Biol Ther · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -